Nevro Corp (NVRO) Shares Up 2.1%
Nevro Corp (NASDAQ:NVRO) shot up 2.1% on Friday . The company traded as high as $96.98 and last traded at $96.34, with a volume of 421,329 shares. The stock had previously closed at $94.37.
A number of brokerages have weighed in on NVRO. Zacks Investment Research upgraded shares of Nevro Corp from a “hold” rating to a “buy” rating and set a $109.00 price objective on the stock in a report on Friday, August 12th. JPMorgan Chase & Co. upped their price objective on shares of Nevro Corp from $84.00 to $100.00 and gave the stock an “overweight” rating in a report on Tuesday, August 9th. William Blair began coverage on shares of Nevro Corp in a report on Tuesday, July 19th. They issued an “outperform” rating on the stock. Leerink Swann restated a “buy” rating on shares of Nevro Corp in a report on Monday, June 6th. Finally, JMP Securities upped their price objective on shares of Nevro Corp from $90.00 to $110.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 9th. Ten analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $102.43.
The stock’s market cap is $2.75 billion. The company’s 50 day moving average price is $86.81 and its 200-day moving average price is $69.76.
Nevro Corp (NASDAQ:NVRO) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.16. The firm had revenue of $55.40 million for the quarter, compared to analysts’ expectations of $45.11 million. The firm’s revenue was up 385.5% on a year-over-year basis. On average, equities analysts forecast that Nevro Corp will post ($1.43) EPS for the current year.
In related news, VP Doug Alleavitch sold 500 shares of Nevro Corp stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $72.00, for a total transaction of $36,000.00. Following the completion of the sale, the vice president now owns 10,961 shares in the company, valued at approximately $789,192. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Michael Enxing sold 1,500 shares of Nevro Corp stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $73.29, for a total transaction of $109,935.00. Following the sale, the vice president now owns 39,463 shares of the company’s stock, valued at approximately $2,892,243.27. The disclosure for this sale can be found here.
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.